The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Clinical trials have demonstrated the benefit of blood pressure (BP) reduction in reducing the risk of cardiovascular and renal complications in patients with diabetes mellitus. Incorporation of agents that inhibit the renin-angiotensin-aldosterone system (RAAS) into antihypertensive regimens has been shown to provide reductions in renal and cardiovascular events that are mediated by both BP-dependent and -independent mechanisms. Recent studies exploring these potential mechanisms have demonstrated a direct role of angiotensin II (ATII) in the pathology of the vasculature and other sites of end-organ injury. In animal models of diabetes, inhibition of the RAAS with angiotensin-converting enzyme (ACE) inhibition or angiotensin type 1 (AT(1)) receptor blockade has been shown to prevent atherosclerosis, an effect that was independent of BP reduction. In addition to its direct effects on the vasculature, ATII also has direct detrimental effects on end organs, including the kidney and the heart, which lead to the development of proteinuria and left ventricular hypertrophy (LVH), respectively. Left ventricular hypertrophy has been shown to be predictive of cardiovascular and renal events, and the benefits of RAAS inhibition with angiotensin receptor blocker therapy are accompanied by a reduction in LVH. In addition to preventing the cardiovascular and renal complications of diabetes, the RAAS blockade has also been shown, in several large randomized clinical trials, to inhibit new onset of diabetes. Recent studies have revealed that many tissues, including pancreatic islets and adipose tissue, have a local RAAS. In the diabetic rat model (Zucker diabetic fatty rats), pancreatic islets exhibit an increased intraislet expression of ACE and AT(1) as well as increased intraislet fibrosis, apoptosis, and oxidative stress. The local RAAS also appears to play a role in the function of the adipocyte. Angiotensin II inhibits adipocyte differentiation, potentially decreasing the storage capacity of adipose tissue. The reduced capacity of adipose tissue to store fatty acids may cause their accumulation in other tissues, leading to insulin resistance and development of diabetes. Collectively, these studies demonstrate that ATII has direct effects on multiple tissues, and inhibition of ATII action in these tissues may be responsible for many of the clinical benefits observed with RAAS inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
Verdecchia, P., Reboldi, G., Angeli, F., Borgioni, C., Gattobigio, R., Filippucci, L., Norgiolini, S., Bracco, C., & Porcellati, C. (2004) · Hypertension · doi:10.1161/01.hyp.0000125726.92964.ab · Cited by 510
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
Lindholm, L. H., Ibsen, H., Borch-Johnsen, K., Olsen, M. H., Wachtell, K., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., et al. (2002) · Journal of Hypertension · doi:10.1097/00004872-200209000-00035 · Cited by 392
Cited by
The RAAS in the pathogenesis and treatment of diabetic nephropathy
Ruggenenti, P., Cravedi, P., & Remuzzi, G. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.58 · Cited by 319
Endothelial inflammation in insulin resistance
SJOHOLM, A., & NYSTROM, T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)70804-7 · Cited by 278
A possible association between primary aldosteronism and a lower β-cell function
Mosso, L. M., Carvajal, C. A., Maiz, A., Ortiz, E. H., Castillo, C. R., Artigas, R. A., & Fardella, C. E. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282861fa4 · Cited by 94
The renin-angiotensin system as a target to solve the riddle of endocrine pancreas homeostasis
Graus-Nunes, F., & Souza-Mello, V. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.191 · Cited by 43
Liao, X., Xiao, J., Li, S.-H., Xiao, L.-L., Cheng, B., Fu, X.-B., Cui, T., & Liu, H.-W. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.07.006 · Cited by 21
Metadata
- Authors
- COOPER, M.
- Venue
- American Journal of Hypertension
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11
- Volume
- 17
- Issue
- 11 Pt 2
- Pages
- S16-S20
- ISSN
- 0895-7061 (ISSN-L)
- OpenAlex
- W2015793109
- Cited by
- 147
- References
- 6
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. https://app.cochat.ai/papers/10.1016/j.amjhyper.2004.08.004
- The paper
- COOPER, M. (2004). The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. American Journal of Hypertension. https://doi.org/10.1016/j.amjhyper.2004.08.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.